SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Daclatasvir

Item No. 23730



CAS Registry No.: 1009119-64-5
Formal Name: N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]*bis*-carbamic acid, C,C'-dimethyl ester
Synonym: BMS 790052
MF: $C_{40}H_{50}N_8O_6$
FW: 738.9
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Daclatasvir is supplied as a solid. A stock solution may be made by dissolving the daclatasvir in the solvent of choice. Daclatasvir is slightly soluble in DMSO and methanol.

Description

Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; K_ds = 8 and 210 nM for the NS5A$^{33-202}$ and NS5A$^{26-202}$ residues of HCV genotype 1b, respectively).[1,2] It potently inhibits HCV replication in multiple HCV replicon genotypes (EC_{50}s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC_{50}s = 9 and 12 pM, respectively).[1] Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.[3,4] Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC_{50}s = 1.5 and 3.27 µM, respectively).[5] Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.

References

1. Gao, M., Nettles, R.E., Belema, M., *et al.* Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* **465(7294)**, 96-100 (2010).
2. Ascher, D.B., Wielens, J., Nero, T.L., *et al.* Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. *Sci. Rep.* **4**, 4765 (2014).
3. Lee, C., Ma, H., Hang, J.Q., *et al.* The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. *Virology* **414(1)**, 10-18 (2011).
4. Guedj, J., Dahari, H., Rong, L., *et al.* Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. *Proc. Nat. Acad. Sci. USA* **110(10)**, 3991-3996 (2013).
5. Furihata, T., Matsumoto, S., Fu, Z., *et al.* Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. *Antimicrob. Agents Chemother.* **58(8)**, 4555-4565 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM